🏛️ Verified NIH Record • Updated 2026-08-18
Long-Term Follow-up of Subjects Who Were Treated With ST-920 (NCT05039866)
Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Sangamo Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Who can join: Review the eligibility criteria below.
Location: University of California, Irvine — Irvine, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of California, Irvine — Irvine, California
- University of South Florida — Tampa, Florida
- Emory University School of Medicine — Atlanta, Georgia
- University of Iowa Hospital and Clinics — Iowa City, Iowa
- University of Minnesota Medical Center — Minneapolis, Minnesota
- Mt. Sinai Hospital — New York, New York
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) — Fairfax, Virginia
- The Royal Melbourne Hospital — Parkville, Victoria
- M.A.G.I.C. Clinic Ltd. — Calgary, Alberta
- University Hospital of Würzburg — Würzburg,
- Addenbrooke's Hospital — Cambridge,
- Royal Free Hospital — London,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Fabry Disease
- A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease — Birmingham, Alabama
- A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease — Birmingham, Alabama
- An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease — La Jolla, California
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease — Birmingham, Alabama
- A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease — Atlanta, Georgia
Explore by condition: All Fabry Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.